A clinical-stage biotech company focused on developing tumor-specific immunotherapies to fight multiple cancer types and which is also developing a COVID-19 vaccine that could aid in the battle against variant strains of the virus.
Covid-19 vaccines aren’t the only ones you should be paying attention to” – and they highlight seven “second-tier” biotechs with catalysts beyond COVID-19 vaccines that may be worth considering.
The final week of January was yet another big one for biotech, with perhaps the most important development of the week being phase III trial results for Novavax’s COVID-19 vaccine.
Of the two “best of both worlds” biotech stocks highlighted in today’s article – “companies with both solid drug-development track records and potential COVID-19 vaccine tailwinds that could net them each significant profits for their role over the next several years”.